Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Myriad Genetics, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) of the November 26, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
If you invested in Myriad stock or options between September 2, 2016 and August 13, 2019 and would like to discuss your legal rights, please fill out the form below. There is no cost or obligation to you. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org.
The lawsuit has been filed in the U.S. District Court for the District of Utah on behalf of all those who purchased Myriad securities between September 2, 2016 and August 13, 2019 (the “Class Period”). The case, Silverman v. Myriad Genetics, Inc. No. 19-cv-00707, was filed on September 27, 2019 and has been assigned to Magistrate Judge Roy K. Altman.
The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose that: (1) GeneSight lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (2) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (3) Myriad had been in ongoing discussions with the FDA regarding the FDA’s requested changes to GeneSight; (4) Myriad’s acquisition of Counsyl—and thereby, Foresight—caused the Company to incur the risk of suffering from lower reimbursement for its expanded carrier screening tests, which had the potential to, and actually did, materialize into a material negative impact on the Company’s revenue; and (5) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Specifically, on August 13, 2019, after market-close, Myriad reported its Fiscal Fourth-Quarter and Full-Year 2019 Financial Results. Therein, the Company reported that revenue in the fourth quarter was two percent below expectations largely due to lower reimbursement for its expanded carrier screening test. Later that day, on the Company’s Earnings Conference Call with investors, Bryan Riggsbee, Myriad’s CFO, revealed that “the FDA requested changes to the GeneSight [Psychotropic] test offering” and that the Company has “been in ongoing discussions with the FDA regarding its request.”
After the announcement, Myriad’s stock price fell from $25.50 per share on August 13, 2019 to $19.05 per share on August 14, 2019—a $6.45 or 42.76% drop.
Myriad Genetics, Inc. (MYGN)
* The submission of this form does not create an attorney-client relationship.
Filed on 09/27/2019
Lead Plaintiff Deadline 11/26/2019
685 Third Avenue 26th Floor
10017 New York, New York
Phone (212) 983-9330
Fax (212) 983-9331
Richard W. Gonnello email@example.com Phone (212) 983-9330 Fax (212) 983-9331